Citigroup Inc Acelrx Pharmaceuticals Inc Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
BUY
$0.18 - $0.29 $4,032 - $6,496
22,402 Added 1120.1%
24,402 $6,000
Q1 2022

May 12, 2022
BUY
$0.28 - $0.61 $560 - $1,220
2,000 New
2,000 $1,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email